17:15:08 EDT Mon 13 May 2024
Enter Symbol
or Name
USA
CA



Medipharm Labs Corp
Symbol LABS
Shares Issued 399,573,661
Close 2023-11-08 C$ 0.07
Market Cap C$ 27,970,156
Recent Sedar Documents

Medipharm Labs to release Q3 2023 results Nov. 14

2023-11-08 17:28 ET - News Release

An anonymous director reports

MEDIPHARM LABS SETS DATE TO REPORT THIRD QUARTER 2023 FINANCIAL RESULTS

Medipharm Labs Corp. will release its third quarter financial results for the three- and nine-month periods ended Sept. 30, 2023, before markets open on Tuesday, Nov. 14, 2023.

Medipharm's executive management team will also host a conference call and audio webcast on Tuesday, Nov. 14, 2023, at 8:30 a.m. Eastern Time to discuss the company's financial results.

Audio conference call dial-in details

Toll-free number: 1-888-330-2454/international number:  1-240-789-2714

Conference ID:   4921762

Participants are asked to dial in approximately 15 minutes before the start of the call.

Audio webcast

An audio webcast will be available on-line.

For those who are unable to participate on the live conference call or webcast, a replay will be available at the company website approximately one day after completion of the call.

About Medipharm Labs Corp.

Founded in 2015, Medipharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a good manufacturing practices certified facility with ISO standard-built clean rooms. Medipharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream purification methodologies, and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. Medipharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets.

In 2021, Medipharm Labs received a pharmaceutical drug establishment licence from Health Canada, becoming the only company in North America to hold a commercial-scale domestic good manufacturing licence for the extraction of multiple natural cannabinoids. The company carries out its operations in compliance with all applicable laws in the countries in which it operates.

In 2023, Medipharm acquired VIVO Cannabis Inc., which expanded Medipharm's reach to medical patients in Canada via Canna Farms medical e-commerce platform, and in Australia and Germany through Beacon Medical Pty. and Beacon Medical GMBH. This acquisition also included Harvest Medical Clinics in Canada, which provides medical cannabis patients with physician consultations for medical cannabis education and prescriptions.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.